Eureka Therapeutics Announces Positive Preliminary Results Of ET190L1-ARTEMIS™ T-Cell China Proof-Of-Concept Human Clinical Study In Relapsed And Refractory B-Cell Lymphoma At ASCO Annual Meeting
Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies
